The treatment landscape of chronic myeloid leukaemia in chronic phase (CP-CML) is continuously changing. During the annual congress of the European Hematology Association (EHA 2022), new strategies to improve the management of CP-CML were presented. These novel strategies include new drugs, alternative treatment strategies to reduce toxicity without affecting efficacy, and new techniques to help identify the best patient subpopulation for treatment-free remission. The highlights of these new strategies are addressed in this article.

(BELG J HEMATOL 2022;13(5):183–7)